Special Reports
Special Reports
January 14, 2021
While there is no cure for MM, a number of treatments are in the research and development pipeline. Clinicians are particularly challenged to treat relapsed or refractory MM.
Special Reports
January 14, 2021
While there is no cure for MM, a number of treatments are in the research and development pipeline. Clinicians are…
Special Reports
December 30, 2020
As the FDA has implemented new programs to streamline its review and approval processes, a total of 47 novel drugs were…
Special Reports
December 17, 2020
An interview with David Andorsky, MD, Rocky Mountain Cancer Centers, Boulder, Colorado.
Special Reports
Deborah Abrams Kaplan, June 17, 2020
The most recent updates in ovarian cancer treatment considerations are highlighted, including notes on staging and…
Special Reports
JCP Editors, November 19, 2019
Coverage of the 2019 Oncology Clinical Pathways Congress includes multiple interviews with faculty members and…
Special Reports
Deborah Abrams Kaplan, September 20, 2019
This special report notes the various resistance and relapse considerations in pathways for multiple myeloma, as well…
Special Reports
JCP Editors, June 20, 2019
This article reviews the leading types of skin cancers in the US in terms of prevalence, treatment guidelines, and…
Special Reports
JCP Editors, June 18, 2019
Breast cancer represents 15.2% of all newly diagnosed US cancer cases and is the second most common cancer in women,…
Special Reports
JCP Editors, December 18, 2018
As FDA has implemented new programs to streamline its review and approval processes, a total of 55 novel drugs were…
Special Reports
December 15, 2017